Indefinite Delivery Contract SPE2DR25D9241

Award Date 9/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to support the medical needs of Department of Defense (DoD) healthcare facilities worldwide. The IDC, valued at $499,999,999 and valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic...
This Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, provides a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 single-award IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic prescription...
This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The $499,999,999 single-award IDC enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $499,999,999, covers the delivery of a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the medical supply needs of military health facilities worldwide. The contract...
The key products and services being delivered under this federal Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc. are a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The IDC, valued at $499,999,999 and valid through November 2026, covers an extensive portfolio of pharmaceutical products including branded and generic prescription drugs, over-the-counter...
The Defense Logistics Agency (DLA) has awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs,...
This Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, aims to provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 single-award IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic...
The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide pharmaceutical products and medical supplies to the Department of Defense (DoD) and other federal government customers. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of branded and generic prescription drugs, over-the-counter medications,...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to the prime contractor DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The single-award IDC, valued at $1,270,341,670.98, covers the delivery of a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. This includes branded and generic prescription drugs,...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 single-award contract covers a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers...

The Indefinite Delivery Contract (IDC) award to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) aims to establish a single-award, Firm Fixed Price contract to provide a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. The $499,999,999 IDC, valid through November 2026, encompasses branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. This IDC aligns with the DLA's upcoming Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) solicitation, which seeks to establish multiple regional contracts to provide worldwide pharmaceutical support to DoD and other government customers. The PPV-G GEN V solicitation is expected to be issued in March 2024, with a total estimated value of $30.3 billion across the base period and three option periods. The contract will be awarded on a Lowest Price Technically Acceptable (LPTA) basis, with the potential use of a reverse auction to determine the final distribution fees.

Generated 6/6/25, 10:01 AM